Condition Lookup
Category:
Connective Tissue and Skeletal Disorders
Number of Conditions: 6
Osteogenesis Imperfecta
Specialty: Genetics
Category: Connective Tissue and Skeletal Disorders
Sub-category: Skeletal Dysplasias
Symptoms:
bone fragility; frequent fractures; blue sclerae; short stature; hearing loss; loose joints
Root Cause:
Mutations in genes (e.g., COL1A1, COL1A2) affecting type I collagen synthesis, leading to brittle bones.
How it's Diagnosed: videos
Clinical evaluation, family history, genetic testing, and radiographic imaging of bones.
Treatment:
Bisphosphonates to increase bone density, physical therapy, orthopedic surgeries, and mobility aids.
Medications:
Bisphosphonates (e.g., alendronate or pamidronate ) to improve bone density; vitamin D and calcium supplements to support bone health.
Prevalence:
How common the health condition is within a specific population.
Affects approximately 1 in 15,000 to 20,000 live births.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Family history; autosomal dominant inheritance is most common.
Prognosis:
The expected outcome or course of the condition over time.
Lifespan can be normal for milder forms; severe types may result in reduced lifespan due to respiratory or fracture complications.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Progressive bone deformities, respiratory issues, reduced mobility, and hearing loss.
Ehlers-Danlos Syndrome
Specialty: Genetics
Category: Connective Tissue and Skeletal Disorders
Sub-category: Connective Tissue Disorders
Symptoms:
hypermobile joints; skin that is stretchy, fragile, or easily bruised; chronic pain; frequent joint dislocations; slow wound healing; dental crowding
Root Cause:
A group of genetic disorders affecting the structure, production, or processing of collagen and related connective tissue proteins.
How it's Diagnosed: videos
Clinical evaluation, family history, genetic testing (e.g., COL1A1, COL5A1 mutations depending on the type).
Treatment:
Symptom management through physical therapy, pain control, joint stabilization, and wound care.
Medications:
Pain management may include acetaminophen , NSAIDs (non-steroidal anti-inflammatory drugs), or low-dose tricyclic antidepressants for chronic pain; no specific medication cures the condition.
Prevalence:
How common the health condition is within a specific population.
Estimated 1 in 5,000 individuals; varies by type.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Family history of the disorder; inherited in autosomal dominant or recessive patterns depending on the type.
Prognosis:
The expected outcome or course of the condition over time.
Highly variable; many lead relatively normal lives with symptom management, but some subtypes can be life-threatening.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Joint instability, chronic pain, vascular rupture (in vascular EDS), organ prolapse, delayed wound healing, and significant skin fragility.
Loeys-Dietz Syndrome
Specialty: Genetics
Category: Connective Tissue and Skeletal Disorders
Sub-category: Aortic and Vascular Disorders
Symptoms:
aneurysms or dissections of the aorta; joint laxity; easy bruising; wide-spaced eyes; bifid uvula; cleft palate; arterial tortuosity
Root Cause:
Mutations in genes such as TGFBR1, TGFBR2, SMAD3, or TGFB2 affecting the transforming growth factor-beta signaling pathway.
How it's Diagnosed: videos
Clinical evaluation, imaging of the vasculature (e.g., echocardiography, CT/MRI), genetic testing.
Treatment:
Regular cardiovascular monitoring, beta-blockers or angiotensin receptor blockers to reduce aortic stress, and surgical repair of aneurysms.
Medications:
Beta-blockers (e.g., atenolol ) or ARBs (e.g., losartan ) to manage blood pressure and reduce strain on the aorta.
Prevalence:
How common the health condition is within a specific population.
Estimated 1 in 100,000; exact prevalence unknown.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Family history; autosomal dominant inheritance.
Prognosis:
The expected outcome or course of the condition over time.
Improved with early diagnosis and management; risks of vascular complications necessitate lifelong monitoring.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Aortic dissection, rupture of aneurysms, joint instability, and organ malformations.
Achondroplasia
Specialty: Genetics
Category: Connective Tissue and Skeletal Disorders
Sub-category: Skeletal Dysplasias
Symptoms:
short stature; disproportionately short limbs; macrocephaly; prominent forehead; midface hypoplasia; limited elbow extension; trident hand appearance
Root Cause:
Mutation in the FGFR3 gene leading to abnormal cartilage development, impairing the process of bone growth (endochondral ossification).
How it's Diagnosed: videos
Clinical evaluation of characteristic physical features, molecular genetic testing for FGFR3 mutations, radiographic imaging of skeletal anomalies.
Treatment:
Multidisciplinary approach including growth hormone therapy (experimental), surgical limb lengthening, physical therapy, and management of complications (e.g., spinal stenosis, sleep apnea).
Medications:
Currently, no specific medications target achondroplasia directly, but vosoritide (a C-type natriuretic peptide analog) is under clinical study to promote bone growth. Pain or complications are managed symptomatically, often with NSAIDs.
Prevalence:
How common the health condition is within a specific population.
Approximately 1 in 15,000 to 40,000 live births globally.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Advanced paternal age increases the risk of new FGFR3 mutations; most cases are sporadic, but inheritance is autosomal dominant.
Prognosis:
The expected outcome or course of the condition over time.
Normal life expectancy with proper management of medical complications; height remains significantly below average.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
spinal stenosis; kyphosis; hydrocephalus; obstructive sleep apnea; ear infections; joint pain; orthopedic abnormalities
Thanatophoric Dysplasia
Specialty: Genetics
Category: Connective Tissue and Skeletal Disorders
Sub-category: Skeletal Dysplasias
Symptoms:
severe shortening of limbs; narrow chest; macrocephaly; frontal bossing; cloverleaf skull; underdeveloped lungs; facial dysmorphism
Root Cause:
Mutation in the FGFR3 gene causing severe disruption of bone growth and skeletal development.
How it's Diagnosed: videos
Prenatal ultrasound showing severe skeletal abnormalities; postnatal clinical examination and genetic testing for FGFR3 mutations confirm diagnosis.
Treatment:
Supportive care focusing on respiratory assistance and management of associated symptoms; no curative treatment exists.
Medications:
There are no specific medications for thanatophoric dysplasia; symptomatic treatments like antibiotics for infections or analgesics for discomfort may be used.
Prevalence:
How common the health condition is within a specific population.
Estimated at 1 in 20,000 to 50,000 live births globally.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
New mutations in FGFR3, primarily sporadic; no significant environmental or familial risk factors identified.
Prognosis:
The expected outcome or course of the condition over time.
Extremely poor; most affected infants die shortly after birth due to respiratory insufficiency or complications related to underdeveloped lungs.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
severe respiratory distress; pulmonary hypoplasia; multiple organ failure
Cleidocranial Dysplasia
Specialty: Genetics
Category: Connective Tissue and Skeletal Disorders
Sub-category: Skeletal Dysplasias
Symptoms:
delayed closure of fontanelles; absent or hypoplastic clavicles; short stature; dental anomalies; wide-set eyes; flat nose bridge; scoliosis
Root Cause:
Mutation in the RUNX2 gene leading to impaired bone and dental development.
How it's Diagnosed: videos
Clinical evaluation of characteristic skeletal and dental abnormalities, genetic testing to confirm RUNX2 mutations, and radiographic imaging.
Treatment:
Orthopedic interventions for skeletal deformities, dental surgery for impacted teeth, and orthodontic treatment for alignment issues.
Medications:
No specific medications are indicated for cleidocranial dysplasia. Pain management, when needed, may include NSAIDs or muscle relaxants.
Prevalence:
How common the health condition is within a specific population.
Estimated at 1 in 1,000,000 individuals worldwide; more common in certain isolated populations.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Autosomal dominant inheritance; 70% of cases are familial, and 30% are de novo mutations.
Prognosis:
The expected outcome or course of the condition over time.
Generally good with appropriate management; life expectancy is normal.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
dental infections; hearing loss; shoulder instability; spinal deformities